My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
October/November 2011
Policy and Advocacy
FDA Influenza Antiviral Guidance for Industry Improved, But Concerns Remain

Revised guidance from the Food and Drug Administration for industry for the development of influenza antiviral drugs is improved, but IDSA remains concerned about the document’s study design recommendations and its interpretation of the available clinical outcomes data. The Society’s comments are online (PDF).
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
MRSA Guidelines Slide Set Available
Drug Approvals, Recalls, Adverse Events Update
Global ID
Sec. Clinton Calls for “AIDS-free Generation”
Global Fund to Fight AIDS, TB, and Malaria Halts New Grants Until 2014
Vaginal Gel Arm of HIV Prevention Study Halted
Policy and Advocacy
CDC Issues New Roadmap for Preventing ID Threats
IDSA Responds to Proposed Common Rule Reforms
FDA Influenza Antiviral Guidance for Industry Improved, But Concerns Remain
Increased Funding for NIH Vital to Nation’s Health
FDA Needs More Funding
Your Colleagues
Check Out “My IDSA” for Latest Member News
Education & Resources
New ID and HIV MOC Modules Available
IDSA Fellows In-Training Exam: Dec. 6 Registration Deadline
Implementing CLSI Breakpoints for Antimicrobial Susceptibility Testing
Top Stories
From the President: Staying Focused in Challenging Times
IDSA 2011: Annual Meeting Reminders
EIN Update: Pertussis Immunization and Protection in an Outbreak
IDSA Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.